KIYATEC
KIYATEC is a life sciences company enabling better in vitro models of complex human biology through perfused 3D cell‐based assays and enabling products. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is a single-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.
KIYATEC
Industry:
Biotechnology Health Diagnostics Life Science
Founded:
2005-01-01
Address:
Greenville, South Carolina, United States
Country:
United States
Website Url:
http://www.kiyatec.com
Total Employee:
11+
Status:
Active
Contact:
864-502-2013
Email Addresses:
[email protected]
Total Funding:
12.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Global Site Tag Nginx
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Seae Ventures
Seae Ventures investment in Venture Round - KIYATEC
VentureSouth
VentureSouth investment in Venture Round - KIYATEC
VentureSouth
VentureSouth investment in Series B - KIYATEC
LabCorp
LabCorp investment in Series B - KIYATEC
VentureSouth
VentureSouth investment in Convertible Note - KIYATEC
VentureSouth
VentureSouth investment in Series B - KIYATEC
VentureSouth
VentureSouth investment in Convertible Note - KIYATEC
VentureSouth
VentureSouth investment in Series A - KIYATEC
VentureSouth
VentureSouth investment in Convertible Note - KIYATEC
Upstate Carolina Angel Network
Upstate Carolina Angel Network investment in Series A - KIYATEC
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-21 | KIYATEC Announces Addition of Chief Commercial Officer Stacy Chick to Executive Team |
Official Site Inspections
http://www.kiyatec.com
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "KIYATEC"
KIYATEC - Crunchbase Company Profile & Funding
KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies.See details»
Our Mission - Kiyatec | About Us
Our Mission: We provide confidence to patients, oncologists, and pharmaceutical companies in their life-changing cancer therapy decisions.See details»
Kiyatec Inc. - LinkedIn
Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create ...See details»
KIYATEC Company Profile | Management and Employees List
KIYATEC Profile and History Started in 2005 and based in Greenville, South Carolina, Kiyatec is a functional precision oncology company that measures the response of each patients live …See details»
Kiyatec Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Kiyatec. Use the PitchBook Platform to explore the full profile.See details»
KIYATEC - Contacts, Employees, Board Members, Advisors & Alumni
KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies.See details»
KIYATEC Company Profile - Office Locations, Competitors, …
KIYATEC has 5 employees at their 1 location and $10.4 m in total funding,. See insights on KIYATEC including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Resources for Healthcare Professionals | Kiyatec
Explore our resources for healthcare professionals including presentations, publications, videos, and more.See details»
KIYATEC | Scientist.com
Kiyatec is continuing to develop robust phenotypic cell-based cancer diagnostics using viable tumor biopsies to assess patient-specific response to available therapeutic agents. By …See details»
KIYATEC - Funding, Financials, Valuation & Investors
KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies.See details»
Org Chart Kiyatec - The Official Board
The org chart of Kiyatec contains its 9 main executives including Eric Perreault.See details»
KIYATEC - VentureRadar
"KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a …See details»
Kiyatec | COLAAB
Kiyatec focuses on advancing drug discovery and personalized medicine through innovative technologies. Kiyatec specializes in 3D cell culture models and predictive analytics to evaluate …See details»
KIYATEC - Tech Stack, Apps, Patents & Trademarks
KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies.See details»
Kiyatec Appoints Eric Perreault as New CEO to Lead Strategic
Jan 7, 2024 As Kiyatec prepares for its next phase of growth and expansion, the company remains focused on advancing functional precision oncology with its 3D cell culture …See details»
Resources for patients and caregivers - Kiyatec
See our resources for patients and caregivers including financial assistance information, sample patient journeys, and more.See details»
Kiyatec Announces Publication of Groundbreaking Study on 3D …
GREENVILLE, S.C., August 29, 2024--Kiyatec, leaders in functional precision oncology, today announced the publication of a pivotal study in Scientific Reports highlighting the impact of the …See details»
KIYATEC Clinical Study Data Shows Test Accurately Predicts Brain …
Jun 17, 2021 KIYATEC announces the publication of new data establishing clinically meaningful prediction of patient-specific responses to standard of care therapy.See details»
Functional precision oncology leader Kiyatec announces Series C …
Kiyatec is an established leader in functional precision oncology, in which clinically relevant laboratory models measure the response of living cells to cancer drugs. In this emerging field, …See details»
Leptomeningeal metastatic disease: new frontiers and future …
2 days ago Leptomeningeal metastatic disease (LMD) arises secondary to the metastatic dissemination of cancer cells into the leptomeninges and cerebrospinal fluid. Novel therapies …See details»